Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
The Cancer Letter's weekly podcast of interviews, discussions, and more to dig deep into the issues that shape oncology.
New episodes every Wednesday.
SUBSCRIBE ON
Spotify Apple Podcast YouTube
Spotify Apple Podcast YouTube
on air
The Galleri MCD vote: What FDA asked its advisors to ignore
Podcast

The Galleri MCD vote: What FDA asked its advisors to ignore

September 30, 2026
The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
PodcastThe Directors

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

September 25, 2026
Vol.52 No.35
By Claire Marie Porter and Paul Goldberg
36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?
Podcast

36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?

September 23, 2026
9/11, mRNA, musical chairs—and an assassination attempt
Podcast

9/11, mRNA, musical chairs—and an assassination attempt

September 16, 2026
As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
Podcast

As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer

September 09, 2026
Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
Podcast

Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field

September 02, 2026
Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
Podcast

Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”

August 26, 2026
Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”
Podcast

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

August 19, 2026
What happened at FDA? Replimune approval raises questions
Podcast

What happened at FDA? Replimune approval raises questions

August 12, 2026
The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access
PodcastThe Directors

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

August 07, 2026
Vol.52 No.31
By Claire Marie Porter and Paul Goldberg

Posts navigation

123…12Next

Trending Stories

  • Is it time to re-assess the practice and practicality of screening colonoscopy?
    Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
  • Michael Caputo appointed to President’s Cancer Panel
    The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship
  • The Galleri MCD vote: What FDA asked its advisors to ignore
  • From “default dead” to living the future of cancer care
    As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
  • The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
    Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
  • FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
    Clinical benefit will not be considered for approval, FDA says

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account